We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · June 14, 2021

Once-Daily Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis

The Lancet

 

Additional Info

The Lancet
Once-Daily Upadacitinib Versus Placebo in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis (Measure Up 1 and Measure Up 2): Results From Two Replicate Double-Blind, Randomised Controlled Phase 3 Trials
Lancet 2021 Jun 05;397(10290)2151-2168, E Guttman-Yassky, HD Teixeira, EL Simpson, KA Papp, AL Pangan, A Blauvelt, D Thaçi, CY Chu, HC Hong, N Katoh, AS Paller, B Calimlim, Y Gu, X Hu, M Liu, Y Yang, J Liu, AR Tenorio, AD Chu, AD Irvine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading